Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Please provide your email address to receive an email when new articles are posted on . The results, presented at the American Society of Retina Specialists annual meeting, showed that after 26 weeks, ...
4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...
-- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- “We have now followed all wet AMD patients in the OPTIC trial for a minimum of a year, and in ...